Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17259214 | 0.84 | KCNH2 (0.39) | KCNH2CACNA1H | |
| SCHEMBL17259307 | 0.84 | CACNA1H (0.44) | KCNH2CACNA1H | |
| SCHEMBL17259301 | 0.82 | KCNH2 (0.39) | KCNH2CACNA1H | |
| SCHEMBL17259314 | 0.77 | MAPT (0.36) | SIRT2SIRT1PPARGPPARDPPARA | |
| SCHEMBL17259316 | 0.77 | SIRT2 (0.34) | SIRT2SIRT1PPARGPPARDPPARA | |
| SCHEMBL17259290 | 0.77 | CA1 (0.38) | SIRT2SIRT1PPARGPPARDPPARA | |
| SCHEMBL17259231 | 0.70 | ALDH1A1 (0.44) | SIRT2SIRT1NR1H2NR1H3 | |
| SCHEMBL17259296 | 0.70 | CACNA1H (0.40) | KCNH2CACNA1H | |
| SCHEMBL17259319 | 0.69 | LMNA (0.46) | KCNH2CACNA1HNR1H2 | |
| SCHEMBL17259242 | 0.68 | SIRT2 (0.49) | SIRT2SIRT1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | claimed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | claimed |
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CACNA1B, CACNA1F, CACNA1G | KCNH2 33/4885CACNA1H 9/4885SIRT2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.